Relationship of Depression to SCD Severity, Health Care Utilization and QoL

抑郁症与 SCD 严重程度、医疗保健利用和生活质量的关系

• 批准号: 7535151
• 负责人: LAURA M. DE CASTRO
• 金额: $ 17.71万
• 依托单位: DUKE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-08-15 至 2010-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7535151
• 关键词: Relationship; Depression; SCD; Severity; Health

DESCRIPTION (provided by applicant): Clinical complications of Sickle Cell Disease (SCD) can affect individuals at nearly any age and lead to deleterious effects on health-related quality of life (HRQoL) and high health care costs. The prevalence of depressive symptoms in SCD patients is high when compared to the general African American population. In accordance with the AHRQ's mission to support health services research that will improve the quality of health care and promote evidence-based decision making, the study will provide us with the appropriate tools to identify risk factors for clinical depression and will further improve our ability to target physical and mental factors that may have a detrimental effect on both medical and QoL outcomes in SCD. The Study Objectives are to 1) Determine the prevalence of depression in SCD patients and its correlation to disease severity, anemia and decline of cognitive function, 2) Determine the relationship between depression and health care utilization by SCD patients and the cost incurred, 3) Identify the association of depression with quality of life measures in SCD patients. Methods: Patient clinical and medical histories will be obtained using a standardized data collection form. The project will take place over a period of two years. Patients will be enrolled over one year. All patients enrolled will be re-assessed after six months from the date of first interview. The prevalence of depression will be assessed using the Beck Depression Inventory. Disease severity will be determined using end-organ severity score calculated at the time of enrollment as well as frequency of hospital admissions during the previous year. The "CNS Vital Signs Test" will be used to assess patients' cognitive functions. Patient diaries and prescriptions will be used to determine the use of narcotics. Health care utilization will be determined prospectively from the time of enrollment using medical records and patient diaries. QoL measures will be assessed using the SF12 short form. Overall, this study will examine the complex relationship between SCD disease-related chronic pain, opioid use, depression, quality of life, and health care utilization. Furthermore, this study will help optimize utilization of medical care by identifying factors that lead to greater health care utilization as well as poorer outcomes.

描述（由申请人提供）：镰状细胞疾病（SCD）的临床并发症几乎可以影响任何年龄的人，并导致对健康相关生活质量（HRQOL）和高医疗保健费用的有害影响。与普通非裔美国人相比，SCD患者的抑郁症状患病率很高。根据AHRQ支持将改善医疗保健质量并促进基于证据的决策的卫生服务研究的使命，该研究将为我们提供适当的工具，以识别临床抑郁症的危险因素，并将进一步提高我们针对SCD中医疗和QoL成果有害影响的身心因素的能力。研究目的是1）确定SCD患者抑郁症的患病率及其与疾病严重程度，贫血和认知功能下降的相关性，2）确定SCD患者与SCD患者的抑郁症与医疗保健利用之间的关系与所产生的成本，3）确定SCD患者的抑郁症与抑郁症的关系。方法：将使用标准数据收集表获得患者临床和医学历史。该项目将在两年内进行。患者将入学一年。自第一次面试之日起六个月后，所有入学的患者将重新评估。抑郁症的患病率将使用贝克抑郁量表进行评估。疾病的严重程度将使用在入学时计算出的最终器官严重程度评分以及上一年的住院频率来确定。 “ CNS生命体征测试”将用于评估患者的认知功能。患者日记和处方将用于确定麻醉品的使用。从入学期间，使用病历和患者日记从入学时间开始，将确定医疗保健利用率。 QOL措施将使用SF12短形式进行评估。总体而言，这项研究将研究与SCD疾病相关的慢性疼痛，阿片类药物使用，抑郁，生活质量和医疗保健利用之间的复杂关系。此外，这项研究将通过识别导致更大的医疗保健利用和较差结果的因素来帮助优化医疗服务的利用。